Senseonics (NYSE:SENS) Trading Up 8.4% – Still a Buy?

Senseonics Holdings, Inc. (NYSE:SENS) shares rose 8.4% during trading on Friday . The stock traded as high as $1.12 and last traded at $1.10. Approximately 4,920,939 shares were traded during trading, a decline of 78% from the average daily volume of 22,190,742 shares. The stock had previously closed at $1.01.

Analyst Ratings Changes

SENS has been the topic of several analyst reports. StockNews.com began coverage on Senseonics in a report on Thursday, December 26th. They issued a “sell” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Senseonics in a research report on Friday, November 15th.

Senseonics Stock Up 10.5 %

The company has a market cap of $664.39 million, a P/E ratio of -8.65 and a beta of 0.64. The stock’s 50-day moving average price is $0.47 and its 200-day moving average price is $0.41. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17.

Senseonics (NYSE:SENS) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. The firm had revenue of $4.26 million for the quarter, compared to the consensus estimate of $4.02 million. As a group, research analysts forecast that Senseonics Holdings, Inc. will post -0.14 EPS for the current year.

Insider Buying and Selling at Senseonics

In other Senseonics news, CEO Timothy T. Goodnow bought 315,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were purchased at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the purchase, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Frederick T. Sullivan purchased 124,933 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $0.38 per share, with a total value of $47,474.54. Following the completion of the transaction, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at $941,960.72. The trade was a 5.31 % increase in their position. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in shares of Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after purchasing an additional 179,103 shares during the period. Symmetry Partners LLC bought a new stake in Senseonics in the third quarter worth about $164,000. Cubist Systematic Strategies LLC boosted its stake in Senseonics by 25.9% in the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after acquiring an additional 85,501 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Senseonics during the 3rd quarter valued at approximately $117,000. Finally, FMR LLC raised its holdings in shares of Senseonics by 48,267.2% in the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after purchasing an additional 167,970 shares during the period. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.